Before Header Navigation - Desktop

  • Healthcare Professionals
  • FIND A CLINIC
  • ACCOUNT
Home
Menu

V2 Main navigation

  • Get Started
    • Get started
    • Am I eligible?
    • Book an Appointment
    • Find a clinic
  • How It Works
    • How it works
    • The Programme
    • The Science
    • The Results
  • Success Stories
  • FAQs
    • FAQs
    • Blog
  • Book a consultation
  • Healthcare Professionals
  • Existing Patients
  • Find a clinic near me
Ip Address
206.204.52.55
Country
United States of America
Country Code
US

 

 

Sitemap

Menu

V2 Main navigation

  • Get Started
    • Get started
    • Am I eligible?
    • Book an Appointment
    • Find a clinic
  • How It Works
    • How it works
    • The Programme
    • The Science
    • The Results
  • Success Stories
  • FAQs
    • FAQs
    • Blog
  • Book a consultation
  • Healthcare Professionals
  • Existing Patients
  • Find a clinic near me

Footer

  • About Allurion
  • Meet The Team
  • Our Story
  • Careers
  • Find a Clinic
  • Blog
  • Our Patents
  • Privacy Policy
  • Quality and Risk
  • Terms of Use
  • Site Map

References

  • * Lenca et al. Obes Surg. 2020 2. Vantanasiri et al. Obes Surg 2020.

  • **  Lenca, Presented at TOS Obesity Week, 2020.

  • *** In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal.

  • **** The Allurion Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up. Its duration is defined by the physician and may vary depending on the physician and patient profile.

  1. Quote from Lucy Jones, dietician http://www.lucyjonesdietitian.co.uk
  2. Clinical Trial Reports: DAA069 and DAA105
  3. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.
  4. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.
  5. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.
  6. Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.
  7. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1
  8. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.
  9. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA
  10. Genco et al. Abstract A185. Oral Presentation at Obesity Week, 2018, Nashville, USA
  11. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
  12. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States
  13. Ienca et al. Presented at TOS 2020
  14. Please read the Elipse balloon IFU for further information: https://www.eifu.online/LAB/02
  15. Ienca et al. Accepted abstract at Obesity Week 2020

About Allurion

Allurion Technologies is dedicated to ending obesity by creating the world’s first full stack weight-loss platform. At the core of this platform is The Allurion Program, a 360-degree weight loss experience featuring the Allurion Gastric Balloon -- the world’s first and only swallowable, procedureless gastric balloon for weight loss -- and the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for clinicians featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion VCS is now available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. Learn more about Allurion online at www.allurion.com. Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Footer

  • About Allurion
  • Meet The Team
  • Our Story
  • Careers
  • Find a Clinic
  • Blog
  • Our Patents
  • Privacy Policy
  • Quality and Risk
  • Terms of Use
  • Site Map
© Allurion 2022

Social links

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn